In conclusion, we found in a large sample of patients with CML treated with BCR-ABL TKIs that when compared with imatinib treatment, patients treated with nilotinib had a higher ratio of ACE, while patients treated with dasatinib showed a lower ratio of cardiovascular and cerebrovascular events. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.